Intermittent fasting in combination with PD-inhibitor treatment as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer

被引：0
作者：
Haag, Jennifer
Lara, Olivia
Zhou, Chunxiao
Hursting, Stephen D.
Bae-Jump, Victoria
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 05期
关键词：
D O I：
10.1158/1557-3265.ENDO24-A008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A008
引用
收藏
页数：2
相关论文
共 28 条
  • [21] Anti-PD-L1 antibody biodistribution, imaging and dosimetry in a pre-clinical breast cancer model: prospects for combination immune checkpoint inhibition and radiopharmaceutical therapy
    Josefsson, Anders
    Park, Sunju
    Jammes, Fabien
    Ray, Sangeeta
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [22] Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer
    Pei, Zhonghua
    Alam, Muzaffar
    Bhola, Neil
    Cleary, Leah
    Drummond, Jake
    Fisher, Marcus
    Fleury, Melissa
    Garcia, Candy
    Givmanesh, Atieh
    Xin Linghu
    McSpadden, Ethan
    Mounir, Zineb
    Neilan, Claire
    Newby, Zach
    Perumal, Senthil
    Steel, Richard
    Sutton, James
    Vaidya, Kedar
    Wagle, Marie-Claire
    Wang, Jianhong
    Yao, Bing
    Lackner, Mark
    Dillon, Michael P.
    CANCER RESEARCH, 2020, 80 (16)
  • [23] Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.
    Conlon, Neil
    McDermott, Martina
    Browne, Brigid
    Roche, Sandra
    O'Neill, Fiona
    Meiller, Justine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective
    P La Rosée
    ME O'Dwyer
    BJ Druker
    Leukemia, 2002, 16 : 1213 - 1219
  • [25] Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia:: a translational perspective
    La Rosée, P
    O'Dwyer, ME
    Druker, BJ
    LEUKEMIA, 2002, 16 (07) : 1213 - 1219
  • [26] Combination treatment with Apo2L/TRAIL and radiation: Pre-clinical study on growth retardation and tumour healing under norm- and hypoxia in the naked mouse model
    Marini, P
    Welz, S
    Stasch, K
    Jendrossek, V
    Budach, W
    Belka, C
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 96 - 96
  • [27] TREATMENT OF THE PRIMARY TUMOR WITH VASCULAR-TARGETED PHOTODYNAMIC THERAPY (VTP) OVERCOMES RESISTANCE TO SYSTEMIC PD-1/PD-L1 INHIBITION: EFFECTS ON PRIMARY TUMOR CONTROL AND PREVENTION OF LUNG METASTASIS IN A PRE-CLINICAL RCC MODEL
    O'Shaughnessy, Matthew
    Murray, Katie
    LaRosa, Stephen
    Monette, Sebastien
    Kim, Kwanghee
    Beluco, Renato
    Fonseca, Corradi
    Scherz, Avigdor
    Coleman, Jonathan
    JOURNAL OF UROLOGY, 2015, 193 (04) : E710 - E710
  • [28] Modulation of the tumor-infiltrating lymphocyte population by PARP inhibitor talazoparib in combination with anti-PD1 treatment significantly enhances overall survival in a murine BRCA1-/- breast cancer model
    Avrutskaya, Anya
    Tschuch, Cordula
    Jensen, Astrid
    Durham, William
    Robinson, Maycee
    Krause, Charles
    O'Koren, Emily
    Kelter, Gerhard
    Peille, Anne-Lise
    Maier, Armin
    Zuurmond, Anne-Marie
    Schueler, Julia
    CANCER RESEARCH, 2019, 79 (13)
123